AnGes, Inc. announces that the first patient was treated with its DNA vaccine for hypertension on April 12, 2018 in the Australian phase I / II clinical study.

This clinical study is being conducted on 24 patients with mild to moderate hypertension, who will be monitored for 12 months after administration of the vaccine to evaluate its safety and efficacy.

The DNA vaccine for hypertension induces antibodies within the body against “Angiotensin II”, a substance responsible for increasing blood pressure. The vaccine is intended to treat hypertension by suppressing the action of this substance. Currently, many oral medications are used for the treatment of hypertension, yet these drugs must be taken daily. In contrast, the DNA vaccine injection is expected to have long-lasting effects with one administration, which would significantly increase the convenience of patients, particularly for elderly patients who have difficulty taking oral medicines.

About AnGes
AnGes is a biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide medicines. In addition to DNA vaccine, AnGes develops HGF plasmid, a gene therapy drug candidate for critical limb ischemia (CLI) and NF-kB Decoy for low back pain. The company is located in Tokyo, Japan and listed on Mothers of Tokyo Stock Exchange, a market for emerging companies.

Forward-Looking Statement
This news release contains forward-looking statements. Any forward-looking statements are based on the current expectations of the company’s management and are subject to significant risks and uncertainties.

###
Disclaimer: This is a translation of a news release published in Japanese. In the event of any deviations between the two language versions, the original document in Japanese shall take precedence.